Search

  1. Leadership

    Page

    … diagnosed with a rare disease, he started ProQR to develop RNA therapies for rare diseases. Before founding ProQR, Mr. … for the ADAR enzymes responsible for adenosine to inosine RNA editing in humans. In addition, his group has led in the …

    A close up of Daniel de Boer

  4. “A new way of designing medicines”

    Story

    … medicines” The potential of this new technology for RNA therapeutics is immense, says Bart Klein, who was at the … Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology …

    A photo of Bart Klein

  5. Axiomer Investor Call

    Webcast

    ProQR management will host an investor conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the recently announced partnership with Lilly. 

  6. Investor Call

    Webcast

    ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs - Management Call

  8. Director, RNA Biology

    Vacancy

    … Director, RNA Biology ProQR Therapeutics is a biotechnology company … of the communities we serve. Our proprietary Axiomer® RNA editing technology platform enables the editing of …

  9. Senior Scientist CMC

    Vacancy

    … USA. ProQR is focused on the development of life changing RNA therapies to meet the unmet need of individuals and … of the communities we serve. Our proprietary Axiomer® RNA editing technology platform enables the editing of …

  10. Director Clinical Operations

    Vacancy

    … USA. ProQR is focused on the development of life changing RNA therapies to meet the unmet need of individuals and … of the communities we serve. Our proprietary Axiomer® RNA editing technology platform enables the editing of …